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Objective. Chronic kidney disease (CKD), including nephrotic syndrome, is a major cause of cardiovascular morbidity and
mortality. )e literature indicates that CKD is associated with profound lipid disorders largely due to the dysregulation of
lipoprotein metabolism which further aggravates the progression of kidney disease. )e present study sought to determine the
efficacy of atorvastatin treatment on hepatic lipid metabolism and renal tissue damage in CKD rats.Methods. Serum, hepatic and
faecal lipid contents and the expression and enzyme activity of molecules involved in cholesterol and triglyceride metabolism,
along with kidney function, were determined in untreated adenine-induced CKD, atorvastatin-treated CKD (10mg/kg/day oral
for 24 days) and control rats. Key Findings. CKD resulted in metabolic dyslipidaemia, renal insufficiency, hepatic lipid accu-
mulation, upregulation of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, acyl-CoA cholesterol acyl-
transferase-2 (ACAT2) and the downregulation of LDL receptor protein, VLDL receptor, hepatic lipase, lipoprotein lipase (LPL),
lecithin–cholesterol acyltransferase (LCAT) and scavenger receptor class B type 1 (SR-B1). CKD also resulted in increased
enzymatic activity of HMG-CoA reductase and ACAT2 together with decreased enzyme activity of lipase and LCAT. Atorvastatin
therapy attenuated dyslipidaemia, renal insufficiency, reduced hepatic lipids, HMG-CoA reductase and ACAT2 protein
abundance and raised LDL receptor and lipase protein expression. Atorvastatin therapy decreased the enzymatic activity of HMG-
CoA reductase and increased enzymatic activity of lipase and LCAT. Conclusions. Atorvastatin improved hepatic tissue lipid
metabolism and renal function in adenine-induced CKD rats.
1. Introduction
Chronic kidney disease (CKD) encompasses a spectrum of
different pathophysiological processes associated with ab-
normal kidney function and a progressive decline in glo-
merular filtration rate. CKD is a serious health problem, and
its prevalence is increasing worldwide due to a rise in the
prevalence of systemic diseases that damage the kidney
[1, 2]. CKD results in the profound alteration of lipid
metabolism which is manifested by hypercholesterolaemia,
hypertriglyceridemia, reduced high density lipoprotein
(HDL) cholesterol, impairedHDLmaturation and decreased
HDL antioxidant and anti-inflammatory properties [3–5].
Furthermore, the associated dyslipidaemia has been shown
to contribute to the progression of kidney disease [6, 7] and
therefore, the treatment of dyslipidaemia in patients with
CKD should ideally confer benefits in terms of both reducing
cardiovascular risk and retarding the progression of renal
disease [8].
Cellular cholesterol homeostasis is regulated by the influx,
biosynthesis, catabolism and efflux of cholesterol. An alter-
ation in these processes can result in the conversion of
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macrophages, mesangial cells and vascular smooth muscle
cells into foam cells [9]. Cholesterol synthesis in the liver is
mediated by several independent pathways including hy-
droxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) re-
ductase, a rate-limiting enzyme in cholesterol biosynthesis,
whereas cholesterol catabolism is primarily mediated by the
LDL receptor [10]. Acyl-CoA cholesterol acyltransferase
(ACAT) 2, a liver specific acyltransferase, catalyses the es-
terification of cholesterol for intracellular storage in the liver.
Furthermore, ACAT is responsible for packaging and re-
leasing cholesterol ester in VLDL and chylomicrons in the
intestine. In the vascular and renal tissues, ACAT plays a
central role in foam cell formation which represents the
earliest lesion in atherosclerosis and glomerulosclerosis
[11, 12]. Lipase is an important enzyme expressed in a variety
of tissues, including liver, skeletal muscle, heart and adipose
tissue and catalyses the hydrolysis of triglycerides contained in
the triglyceride-rich lipoproteins, such as VLDL and chylo-
microns [13]. )us, lipase deficiency has been shown to
markedly elevate serum triglycerides and VLDL levels and
impair chylomicron clearance in CKD patients [14] and in
experimentally-induced CKD animals [15]. CKD is consis-
tently associated with reduced plasma HDL cholesterol
concentration, impaired maturation of cholesterol ester-poor
HDL-3 (nascent HDL) to cholesterol ester-rich HDL-2
(mature HDL), increased HDL triglycerides and depressed
plasma apoA-I [16]. )ese abnormalities are primarily due to
CKD-induced dysregulation of several important proteins
such as lecithin-cholesterol acyltransferase (LCAT) [17, 18],
scavenger receptor class B type 1 (SR-B1) [19–21] and ATP
binding cassette A1 (ABCA1) [22].
Statins, or HMG-CoA reductase inhibitors, are the most
common, clinically used lipid-lowering drugs and have been
demonstrated to be effective in reducing LDL levels and
cardiovascular mortality in the general hyperlipidaemic
population. Considering the clinical benefits of statins in
general nonuremic population, a similar benefit also for
patients with CKD may be assumed. Furthermore, ator-
vastatin showed a renoprotective effects in diabetic mice via
the downregulation of RhoA and upregulation of Akt/GSK3
signaling pathway in kidney [23]. Shibashaki et al. [24]
showed that pitavastatin reduces inflammation within
atherosclerotic lesions in mice with late-stage renal disease.
Furthermore, atorvastatin attenuates kidney function im-
pairment, proteinuria and mesangial cell proliferation in
bovine gamma-globulin rat model of chronic glomerulo-
nephritis which is the major cause of end-stage kidney
disease [25]. Although there are several observational studies
to evaluate the effects of statins on CKD-induced dyslipi-
daemia and associated cardiovascular death in humans,
there are few preclinical studies of statins on CKD-induced
dyslipidaemia [26]. Furthermore, most of the available lit-
erature data on the effects of statins in CKD patients are
extrapolated from post hoc analyses of large prospective
interventional trials carried out on subjects with established
cardiovascular diseases, but not specifically addressing CKD
patients [27–29]. Several large clinical trials showed a
conflicting result on renoprotective effects of statin in CKD
populations [30]. Nevertheless, the chronic administration
of statin markedly improved circulatory lipids abnormality
[17, 31] and also can ameliorate markers of endothelium
dysfunction and offers a significant protective effect against
the development of renal failure in 5/6 nephrectomised CKD
rats [32]. )us, the present study explored the effects of
atorvastatin on the lipid metabolism and renal function in
adenine-induced CKD rats.
2. Materials and Methods
2.1. Chemicals Used. Atorvastatin was purchased from
Sigma (St. Louis, MO, USA). Cholesterol, triglyceride, HDL
cholesterol, albumin, creatinine and urea nitrogen di-
agnostic kits were obtained from PM Separations (Capalaba,
DC, USA), while the diagnostic kits for nonesterified free
fatty acids (NEFA) and bile acids were obtained from Wako
Diagnostics (Osaka, Japan). Electrophoresis and electro-
blotting consumables were purchased from Bio-Rad (Her-
cules, CA, USA). All primary and secondary antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Enhanced chemiluminescence kit was obtained from
Bio-Rad (Hercules, CA, USA). All other chemicals used in
the studies were of analytical or molecular biology grade
unless otherwise specified.
2.2. Animals and Diets. Adult male Sprague-Dawley rats
(150–200 g) obtained from the Animal Resource Centre
(Canning Vale, WA, Australia) were used in the studies.
Upon arrival, the rats were weight-matched and housed in
polypropylene cages (3 per cage) to minimise isolation
stress.)e animal facility was well ventilated andmaintained
at an ambient temperature of 24± 2°C with 50–60% relative
humidity with 12-hour light and dark cycle. )e rats were
acclimatised to the laboratory conditions for one week prior
to experimentation and provided with standard diet and
water ad libitum. Both the standard (catalogue no.: AIN93G)
and the adenine (0.75% w/w) supplemented (catalogue no.:
SF15-082) rat pellet diets were supplied by Speciality Feeds
(Glen Forrest, WA, Australia). )e standard diet contained
(in weight percentage) approximately: 60% carbohydrate,
17.5% protein, 5% fat, 7% crude fibre, and the adenine-
supplemented diet contained 0.75% adenine in the standard
diet. )e use and care of the animals in this experimental
protocol was approved by the Institutional Animal Care and
Ethics Committee (Approval Number: A11259) of the
Western Sydney University, Australia, following the Aus-
tralian National Health and Medical Research Council
(NHMRC) guidelines on the “Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes.”
2.3. Experimental Design and Treatments. )e rats were
weight-matched and divided into three groups, each con-
sisting of five to six rats. )e control and CKD rats were fed
with standard diet and adenine-supplemented diet (0.75% w/
w adenine in standard diet), respectively, and treated with
vehicle (1% sodium CMC) by oral gavage once daily for 24
days. )e atorvastatin group (denoted as a CKD+ATV) was
fed with adenine-supplemented diet and treated with
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atorvastatin at a dose of 10mg/kg by oral gavage once daily for
24 days. On day 21, the rats were placed individually in
metabolic cages, acclimatised for two days, and the 24-hour
faeces and urine were collected on day 24. )e urine samples
were centrifuged at 1000 rpm for 10 minutes to remove food
particles and debris and the supernatants were stored at − 20°C
until analysis. )ereafter, the rats were anesthetised with an
intraperitoneal injection of ketamine (75mg/kg) and xylazine
(5mg/kg) cocktail, and blood samples (approximately 3mL)
were collected from cardiac puncture and allowed to clot for
30 minutes before centrifuging at 3000 rpm for 15 minutes.
)e serum was separated and stored at − 20°C until bio-
chemical analysis. After blood collection, the liver, kidney,
heart, skeletal muscle and epididymal fat tissue of each rat
were immediately dissected, weighed and snap frozen in
liquid nitrogen, and stored at − 80°C until cellular and mo-
lecular studies. At the end of the procedure, the rats were
euthanised by exsanguination from the abdominal aorta.
2.4. Biochemical Estimation
2.4.1. BodyWeight, Food Intake andWater Intake. )e daily
body weights were recorded in all groups of rats every day
between 9 AM and 10 AM and continued up to 24 days. )e
24-hour food and water intake from each cage were de-
termined daily at 10 AM.
2.4.2. Serum Biochemical Parameters. Serum total choles-
terol, triglycerides, HDL cholesterol, NEFA, urea nitrogen,
albumin and creatinine were estimated using the com-
mercial diagnostic kits following the manufacturer’s in-
structions. Serum very low density lipoprotein (VLDL)
cholesterol and low density lipoprotein (LDL) cholesterol





LDL � total cholesterol − [HDL + VLDL].
(1)
Atherogenic index (AI) and coronary risk index [26] as
measures of the extent of atherosclerotic lesions and cor-
onary atherosclerosis development, respectively, were cal-
culated using serum total cholesterol and HDL cholesterol of
different groups of rats using the following mathematical
formulae [34]:
AI �








2.4.3. Liver Lipid Content. Total lipids were extracted from
the liver samples by the modified method of Hara and Radin
[35] as described by Raubenheimer et al. [36]. Briefly, 75–
100mg aliquots of liver were homogenised in 20 volumes of
isopropanol, shaken in an orbital shaker for 45 minutes and
centrifuged at 3000 g for 15 minutes, and the supernatant
was analysed for hepatic cholesterol, triglycerides and NEFA
using commercial diagnostic kits following the manufac-
turer’s instructions.
2.4.4. Urine Biochemical Parameters. Total urinary protein
(proteinuria) was estimated based on the method of Brad-
ford following the manufacturer’s instructions (Bio-Rad,
Hercules, CA, USA), with absorbance measured at 595 nm
using)ermoMultiskanmicroplate reader. Urine creatinine
and urea nitrogen (UUN) were estimated using the com-
mercial diagnostic kits following the manufacturer’s in-
structions. Creatinine clearance was mathematically
calculated as a clinical index of kidney function using serum
and urine creatinine values as per the following formula [37]:
creatinine clearance (mL/min/kg)� [urinary Cr (mg/dL)×
urinary volume [38]/serum Cr (mg/dL)]× [1000/body
weight (g)]× [1/1440 (min)].
2.4.5. Faecal Lipid Content Estimation. )e faeces samples
collected during the last 24 hours of the treatment protocol
were weighed and dried at 110°C for 24 hours. After drying
and reweighing, the faeces samples were powdered using a
mortar and stored at − 20°C until analysis. )e total lipids
from rat faeces were extracted by the modified method of
Folch et al. [39] as described by Kraus et al. [40]. Total
cholesterol and triglycerides in rat faeces were estimated
using an enzymatic colorimetric assay based on the cho-
lesterol oxidase method following the manufacturer’s
instructions (PM Separations, USA), with absorbance
measured at 550 nm using a UV-VIS spectrophotometer.
)e total bile acids from rat faeces were extracted by the
method of De Wael et al. [41] and estimated using a
colorimetric assay kit based on an enzymatic cholesterol
method following the manufacturer’s instructions (Wako
Diagnostic, Japan), with absorbance measured at 560 nm
using a UV-VIS spectrophotometer.
2.5.5eExpression ofMarkerProteins in theVariousTissues of
CKD Rats
2.5.1. Tissue Protein Extraction. Frozen tissue (i.e., liver,
skeletal muscle, heart and adipose tissue) samples were
homogenised on ice for 30 seconds using a Tissue Master
homogeniser (Omni International, GA, USA) with five
volumes of radio immunoprecipitation assay (RIPA) buffer
(pH 8.0) containing 50mM Tris, 150mM NaCl, 1% Triton
X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, and 10 μL/mL protease and phosphatase inhibitors
cocktail. )e homogenates were centrifuged at 4°C at
10,000 g for 15 minutes, and the supernatants were collected.
Protein concentrations were measured by the Bradford assay
using bovine serum albumin as standard.
2.5.2. Western Blot Analysis. )e samples were mixed with
loading buffer; proteins were denatured by heating at 95°C
for 7 minutes, and 25 or 50 μg of total protein was elec-
trophoretically resolved on 8 to 10% Mini-PROTEAN®TGX™ Precast gels (Bio-Rad, Australia) at 120V for 90
minutes and then transferred onto a nitrocellulose
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membrane (Bio-Rad, Australia) using a Trans-Blot Turbo®Transfer System (15V for 30min) or Mini Trans-Blot® Cell(100V for 1 hour). After blotting, the membranes were
blocked with 5% nonfat dry milk for 1 hour at room tem-
perature. )e membranes were then washed three times for 5
minutes each with Tris-buffered saline-0.1% Tween (TBST,
pH 7.6) and incubated overnight at 4°C with mouse anti-
HMG-CoA reductase (1 :1000), mouse anti-LDLR (1 :1000),
goat anti-ACAT2 (1 :1000), rabbit anti-hepatic lipase (1 :
1000), mouse anti-lipoprotein lipase (1 :1000), mouse anti-
VLDLR or mouse anti-LCAT (1 : 500), or goat anti-SR-B1 (1 :
500) antibody (Santa Cruz, Biotechnology, CA, USA) diluted
with TBST. Blots were then again washed three times for 5
minutes each with TBST and incubated for 1 hour at room
temperature with an appropriate horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnology,
CA, USA) diluted at 1 :10,000 with phosphate-buffered saline
(PBS, pH 7.4).)emembranes were again washed three times
for 5 minutes each with TBST and incubated with enhanced
chemiluminescence reagent (Clarity™ Western ECL, Bio-
Rad, Australia) for 1 minute at room temperature. Immune
complexes were detected after exposing the blots to Chem-
iDoc™ XRS system (Bio-Rad, Australia) at various time
points. Quantitative image analysis was performed using NIH
Image software (Image J) to determine the intensity of the
protein signal, which was expressed relative to the amount of
β-actin used as an internal control.
2.6.5eActivity ofMarker Enzymes inVariousTissues of CKD
Rats. )e activity of HMG-CoA reductase enzyme in the
liver was assayed by the method of Rao and Ramakrishnan
[42]. )e enzyme activity of ACAT2 was performed using
the fluorometric acetyltransferase activity assay kit (Abcam
ab204536) as per the manufacturer’s instructions, with
fluorescence measured at Ex/Em� 380/520. )e enzyme
activity of LPL was performed using the fluorometric LPL
activity assay kit (Roar Biomedical Inc) as per the manu-
facturer’s instructions, with fluorescence measured at Ex/
Em� 370/450. )e LPL activity assay results were normal-
ised to the amount of protein (nmol/mg of tissue or serum
protein) and determined using the Bradford assay using
bovine serum albumin as standard. )e enzyme activity of
LCAT was performed using the fluorometric LCAT activity
assay kit (Roar Biomedical Inc.) as per the manufacturer’s
instructions, with fluorescence measured at two different
wavelengths: (i) Ex/Em� 340/390 and (ii) Ex/Em� 340/470.
)e ratio of the two emission intensities (390 nm/470 nm)
was used to express LCAT activity.
2.7. Data and Statistical Analysis. )e results were expressed
as means± SEM To analyse the quantitative differences
among the experimental groups, the data were subjected to
the analysis of variance using the GraphPad 7.03 (GraphPad
Software Inc., California, CA, USA) statistical software. Post
hoc comparisons were made using Dunnett’s multiple
comparisons test. In all tests, p< 0.05 was used as the cri-
terion for statistical significance.
3. Results
3.1. General Laboratory Data. )ere was no significant
difference in the initial body weights (194.2 ± 5.77 g to
198.83 ± 2.41 g, day 0 body weight, data not shown in
Table 1) between different experimental groups. However,
by the end of week 1, CKD rats exhibited significant de-
crease in body weight compared to control rats (data not
shown) and this difference continued till the end of the 24-
day treatment period (Table 1). However, the group treated
with atorvastatin (10mg/kg) did not show a significant
improvement in body weight compared with CKD rats at
the end of the 24-day treatment period. CKD rats signif-
icantly increased water intake compared with control rats
at the end of the 24-day treatment period, while atorvas-
tatin-treated rats showed significant reduction in water
intake compared with CKD rats. In addition, the mean
daily food intake was significantly decreased in CKD and
atorvastatin-treated rats compared to control rats. Nev-
ertheless, the mean daily food intake was not significantly
different between CKD and atorvastatin-treated rats.
Moreover, the higher urinary volume of CKD rats, which is
hallmark of the renal damage, was significantly attenuated
by atorvastatin treatment. In addition, right and left kidney
weights of CKD rats (normalised to body weight) were
significantly increased compared to those of the control
rats. However, CKD-induced kidney weight gain was
significantly reduced by atorvastatin treatment.
3.2. Serum,Tissue andFaecalLipidData. )e serum, hepatic,
renal and faecal lipid profile data are shown in Table 2. )e
CKD rats exhibited a significant increase in serum total
cholesterol, LDL cholesterol, VLDL cholesterol, tri-
glycerides, AI, CRI and NEFA and decrease in serum HDL
cholesterol. Chronic atorvastatin administration resulted in
a significant reduction in serum total cholesterol, LDL
cholesterol, VLDL cholesterol, triglycerides, AI, CRI and
NEFA but did not significantly increase serum HDL cho-
lesterol compared to CKD rats.)e CKD rats had significant
elevation of cholesterol, triglycerides, and NEFA in the liver
which was significantly reduced by atorvastatin treatment.
Moreover, faecal total lipids, cholesterol, triglycerides, and
total bile acids were not changed among the experimental
groups.
3.3. Kidney Function Tests. As expected, the CKD rats had a
significant elevation of serum creatinine and blood urea
nitrogen concentrations and urinary protein excretion (14-
fold) compared to control rats. Furthermore, CKD rats
exhibited a significant decrease of urine creatinine, urine
urea nitrogen, creatinine clearance and serum albumin
levels. Atorvastatin treatment significantly lowered serum
creatinine, blood urea nitrogen concentrations and urinary
protein excretion and significantly elevated urine creatinine,
urine urea nitrogen, creatinine clearance and serum albumin
levels compared to CKD rats (Table 3).
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3.4. Cellular Effects of Atorvastatin on HMG-CoA Reductase,
ACAT2 and LDL Receptor in the Liver of CKDRats. We have
shown that chronic atorvastatin administration reduced
serum and hepatic cholesterol and LDL cholesterol in CKD
rats. As expected, HMG-CoA reductase and ACAT2
abundance and activity were significantly increased in the
liver of CKD rats than those found in the control rats. )is
was associated with a significant reduction of LDL receptor
abundance in the liver tissues of CKD rats compared to the
corresponding values found in the control rats. )e ad-
ministration of atorvastatin normalised the HMG-CoA and
ACAT2 expression and enzyme activity in the liver of CKD
rats. Atorvastatin also significantly increased the LDL
receptor protein expression in the liver when compared to
CKD rats (Figure 1).
3.5. Cellular Effects of Atorvastatin on LCATand SR-B1 in the
Liver of CKDRats. In the present study, atorvastatin showed
a tendency to improve the HDL cholesterol in the serum of
CKD rats but did not reach significance. However, ath-
erogenic and coronary risk indices (HDL to total cholesterol
ratio) were significantly decreased upon atorvastatin treat-
ment. )erefore, we investigated the underlying molecular
mechanism responsible for the observed effects by mea-
suring the expression and enzyme activity of the marker
Table 1: Effect of atorvastatin treatment on general laboratory parameters after 24 days in adenine-induced CKD rats.
CLT CKD CKD+ATV
Body weight (g) 380.4± 6.04 218.08± 5.22### 231± 7.61
Average water intake (mL/day) 41.58± 0.59 52.91± 1.13### 46.22± 0.35∗∗∗
Average food intake (g/day) 29.04± 2.24 18.78± 0.41### 18.38± 0.18
Urinary volume (mL/24 h) 24.40± 2.21 37.00± 1.58### 27.83± 2.02∗∗
L. kidney weight (g/100 g body wt) 0.43± 0.02 2.44± 0.08### 1.60± 0.11∗∗∗
R. kidney weight (g/100 g body wt) 0.41± 0.02 2.38± 0.11### 1.46± 0.12∗∗∗
Values represent the mean± SEM of 5 to 6 rats (n� 5 to 6). Significant difference from control: ###p< 0.001. Significant difference from CKD: ∗∗p< 0.01,
∗∗∗p< 0.001. ATV: atorvastatin; CLT: control; CKD: chronic kidney disease.
Table 2: Effect of atorvastatin treatment on lipid parameters of various biological samples after 24 days in adenine-induced CKD rats.
CLT CKD CKD+ATV
Serum total cholesterol (mg/dL) 82.11± 8.38 153.28± 4.64### 97.30± 11.32∗∗
Serum LDL cholesterol (mg/dL) 32.97± 14.41 115.28± 5.23### 60.56± 13.08∗∗∗
Serum VLDL cholesterol (mg/dL) 13.72± 0.76 21.84± 0.34### 14.02± 1.94∗∗∗
Serum HDL cholesterol (mg/dL) 35.42± 3.10 16.16± 3.33### 22.08± 2.80ns
Serum triglycerides (mg/dL) 68.59± 3.82 109.19± 1.71### 70.09± 9.71∗∗∗
Serum NEFA (μEq/L) 872.63± 18.03 1099.16± 16.36# 767.41± 92.22∗∗
Atherogenic index 1.31± 0.17 10.63± 2.28### 3.88± 0.93∗∗∗
Coronary risk index 2.31± 0.17 11.63± 2.28### 4.88± 0.93∗∗∗∗
Liver cholesterol (mg/g of liver) 0.38± 0.07 4.95± 1.30### 2.42± 0.44∗∗∗
Liver triglycerides (mg/g of liver) 2.55± 0.73 10.51± 1.39### 4.09± 1.32∗∗∗
Liver NEFA (mg/g of kidney) 0.73± 0.05 1.20± 0.06## 0.97± 0.15ns
Total faecal lipid (mg/g of dried faeces) 44.82± 3.9 51.33± 7.80 46.33± 0.63ns
Faecal cholesterol (mg/g of dried faeces) 1.33± 0.16 2.21± 0.66 2.26± 0.22ns
Faecal triglyceride (mg/g of dried faeces) 3.21± 0.33 3.71± 0.53 3.24± 0.15ns
Total bile acid (μmol/g of dried faeces) 46.23± 1.42 52.13± 6.25 54.30± 5.86ns
Values represent the mean± SEM of 5 to 6 rats (n� 5 to 6). Significant difference from control: #p< 0.05 and ###p< 0.001. Significant difference from CKD:
∗∗p< 0.01 and ∗∗∗p< 0.001. No significant difference from CKD: ns; CLT: control; CKD: chronic kidney disease.
Table 3: Effect of atorvastatin treatment on kidney biochemical parameters after 24 days in the serum and urine of adenine-induced CKD
rats.
CLT CKD CKD+ATV
Serum creatinine (mg/dL) 0.45± 0.07 2.62± 0.08### 1.49± 0.26∗
Urine creatinine (mg/dL) 28.69± 2.61 11.23± 0.34### 19.86± 0.91∗∗∗
Creatinine clearance (ml/min/kg) 3.07± 0.20 0.63± 0.13### 1.29± 0.25∗∗
Blood urea nitrogen (mg/dL) 4.46± 1.53 13.09± 1.19## 5.95± 0.75∗∗
Urine urea nitrogen (mg/dL) 14.28± 1.06 5.95± 0.75### 10.11± 1.10∗∗
Serum albumin (mg/dL) 8.41± 0.32 5.47± 0.08### 6.70± 0.29∗
Urine protein (mg/24 h) 5.52± 0.83 70.73± 4.14### 9.71± 2.60∗∗∗
Values represent the mean± SEM of 5 to 6 rats (n� 5 to 6). Significant difference from control: ##p< 0.01 and ###p< 0.001. Significant difference from CKD:
∗∗p< 0.05, ∗∗p< 0.01, and ∗∗∗p< 0.001. CLT: control; CKD: chronic kidney disease.
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protein responsible for HDL synthesis in the liver of CKD
rats (Figure 1). Our investigation revealed that LCAT and
SR-B1 (HDL receptor) were significantly decreased in the
liver of untreated CKD rats. Atorvastatin administration
improved the LCAT and SR-B1 protein abundance. Fur-
thermore, atorvastatin also improved the suppressed LCAT
enzyme activity in the liver of CKD rats (Figure 1).
3.6. Cellular Effects of Atorvastatin on Lipase and VLDL
Receptor in Various Tissues of CKD Rats. Our results indicate
that long-term atorvastatin administration reduced serum and
hepatic triglycerides and triglyceride-rich lipoprotein (VLDL)
and thereby, effectively reduced CKD-induced hyper-
triglyceridemia in CKD rats. It can be postulated that the
observed triglycerides lowering effects could be due to lipase
and VLDL receptor deficiencies in various tissues such as liver,
skeletal muscle, heart and adipose tissue. )e underlying mo-
lecular mechanisms of atorvastatin were studied by measuring
the lipase and VLDL receptor protein expression in the liver,
skeletal muscle, heart and adipose tissue of CKD rats. Fur-
thermore, we havemeasured the enzyme activity of lipase in the
liver, heart, skeletal muscle, adipose tissue and serum of CKD
rats. )e western blot data are shown in Figure 2. In agreement
with previous studies [13–15], the lipase abundance was sig-
nificantly reduced in the liver (hepatic lipase), skeletal muscle,
heart and adipose tissue (lipoprotein lipase) of the untreated
CKD rats when compared with the control rats. )is was ac-
companied by the marked reduction of VLDL receptor in the
skeletal muscle, heart and adipose tissue of the untreated CKD
rats compared to control rats. Atorvastatin supplementation
normalised the lipase expression in the liver (hepatic lipase),
skeletal muscle, heart and adipose tissue.Moreover, atorvastatin
did not alter the VLDL receptor protein expression in the
skeletal muscle, heart and adipose tissue compared to
untreated CKD rats. Furthermore, lipase enzyme activity
in various tissues as well as in the serum was significantly
reduced in CKD rats. However, atorvastatin increased the
lipase enzyme activity in the liver, skeletal muscle, heart,
adipose tissue and serum (Figure 3).
4. Discussion
In the present study, the protective effects of atorvastatin were
examined on hepatic lipid derangement and renal damage in
an adenine-induced rat model of CKD. Long-term feeding of
adenine is known to suppress the excretion of various ni-
trogenous compounds due to renal tubular occlusion and
produce metabolic abnormalities in rats that closely mimic
CKD in humans [43]. To our knowledge, this is the first study
to use an adenine-induced rat model of CKD to investigate the
protective effects of atorvastatin on hepatic lipid metabolism.
)e untreated CKD rats exhibited a 2-fold rise in
serum and hepatic total cholesterol and a nearly 4-fold
increase in serum LDL cholesterol concentration. )is was
associated with a marked reduction in hepatic tissue LDL
receptor abundance confirming earlier reports in the rats
with 5/6 nephrectomy-induced CKD [44] and in the rats
with puromycin-induced nephrotic syndrome [45].
Atorvastatin administration resulted in a marked re-
duction in serum total and LDL cholesterol concentration.
)is was accompanied by the amelioration of hepatic LDL
HMGCR
β-Actin






















































































































































































































































Figure 1: Effects of atorvastatin on expression and enzymatic activity of various proteins in the liver of adenine-induced CKD rats. (a)
HMG-CoA reductase (HMGCR), (b) ACAT2, (c) LDL receptor (LDLr), (d) LCAT, and (e) SR-B1 protein expression as determined by
western blot analysis in liver of rats treated for 24 days either with normal diet (control) or adenine-supplemented diet (CKD) alone or with
atorvastatin (CKD+ATV). Enzyme activity of (f ) HMG-CoA reductase, (g) ACAT2, and (h) LCAT in the liver of control, CKD, and
atorvastatin-treated rats. Relative optical density was calculated relative to β-actin used as internal control. Each bar represents the
mean± SEM of 5–6 rats calculated. Significant difference from control: #p< 0.05, ##p< 0.01, and ###p< 0.001. Significant difference from
CKD: ∗p< 0.05 and ∗∗p< 0.01.
6 BioMed Research International
receptor deficiency. )e decline in serum LDL cholesterol
in atorvastatin-treated CKD rats could be, at least in part, due
to attenuation of LDL receptor deficiency and restoration of
hepatic LDL receptor. )e mechanism by which atorvastatin
reverses hepatic LDL cholesterol in CKD is unclear. However,
it may represent a compensatory response to the inhibition of
cellular cholesterol biosynthesis via HMG-CoA reductase
inhibition. )e untreated CKD rats in the present study
exhibited a significant decrease in serum HDL cholesterol and
significantly increase serum total cholesterol-to-HDL cho-
lesterol, representing atherogenic and coronary risk profile.
)is was also associated with the severe reduction in hepatic
LCAT activity and LCAT and HDL receptor (SR-B1) protein
expression. )ese results confirm the earlier reports in animal
and humans with CKD [16, 18, 46]. LCATand HDL receptor
deficiencies can be responsible for impaired HDL maturation,
defective reverse cholesterol transportation, and atherogenic
and coronary risk profile in patients and CKD animals.
Atorvastatin administration for 24 days reversed, at least in
part, CKD-induced LCAT deficiency as evident by increased
hepatic LCAT activity and protein expression. Moreover, the
hepatic HDL receptor was also normalised by atorvastatin
administration. )e correction of LCAT and HDL receptor
deficiencies was most likely responsible for the trend (but not
significant) in the rise of serum HDL cholesterol levels ob-
served in atorvastatin-treated CKD animals. In addition, the
amelioration of proteinuria (which is the defining feature of
CKD) with atorvastatin administration must have contributed
to the observed improvements of the associated LDL andHDL
receptor deficiencies. )erefore, the alleviation of CKD-in-
duced altered cholesterol metabolism in the present study by
atorvastatin could be, at least in part, due to its renoprotective
effects, which needs further investigation.
ACAT catalyses intracellular esterification of cho-
lesterol, and as such involved in the intestinal absorption
of cholesterol, hepatic assembly of apoB-containing li-
poproteins, foam cell formation and atherogenesis [47].
In agreement with previous studies [17, 48], the CKD rats
employed in this study showed marked upregulation of
liver-specific ACAT2 activity and expression, which
significantly decreased upon atorvastatin administration.
Increased ACAT2 enzyme activity and protein expres-
sion enhanced the esterification of free cholesterol in the
endoplasmic reticulum. )is further reduced the total
free cholesterol pool which, in turn, resulted in the
upregulation of HMG-CoA reductase and, hence, in-
creased cholesterol biosynthesis (also exhibited in our
untreated CKD rats). However, HMG-CoA reductase
inhibition by atorvastatin could be the reason of the
observed ACAT2 activity and protein expression in-
hibition, but this needs further investigation.
In accordance with previous studies, our untreated CKD
rats displayed the marked elevation of serum triglycerides,

























































































































































































































































































Lane 1 Lane 2 Lane 3
(g)
Figure 2: Effects of atorvastatin on protein expression of lipase and VLDL receptor in various tissues of adenine-induced CKD rats. Lipase
expression in (a) liver, (b) skeletal muscle, (c) heart, and (d) adipose tissue and VLDL receptor expression in (e) skeletal muscle, (f ) heart,
and (g) adipose tissue as determined by western blot analysis in liver of rats treated for 24 days either with normal diet (control) or adenine-
supplemented diet (CKD) alone or with atorvastatin (CKD+ATV). Relative optical density was calculated relative to β-actin used as internal
control. Each bar represents the mean± SEM of 5–6 rats. Significant difference from control: ##p< 0.01. Significant difference from CKD:
∗∗p< 0.01. SM, skeletal muscle; AT, adipose tissue; HL, hepatic lipase; LPL, lipoprotein lipase.
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and NEFA levels were also significantly higher in CKD rats.
)is was associated with a significant reduction in lipase
enzyme activity and protein expression in the liver (hepatic
lipase), heart, skeletal muscle, adipose tissue and serum.
Furthermore, the CKD rats in this study showed marked
downregulation of VLDL receptor in these tissues. )us,
the results presented in this study substantiate the claim
that CKD-induced hypertriglyceridemia could be due, at
least in part, to lipase deficiency [49, 50]. Long-term
atorvastatin administration in the CKD rats results in a
significant decline in serum and hepatic triglyceride and
NEFA levels, as well as serum VLDL levels. )is was ac-
companied by the upregulation of lipase protein expression
and enzyme activity in hepatic and various extrahepatic
tissues. Furthermore, hypertriglyceridemia in CKD rats is
associated with impaired maturation of HDL-3 to HDL-2
mediated by LCAT deficiency which further contributes to
defective lipolysis and clearance of triglyceride-rich lipo-
proteins (i.e. VLDL and chylomicrons) in circulation.)us,
it can be postulated that improvement in hyper-
triglyceridemia in the atorvastatin-treated CKD rats could
be due to the improvement in HDL metabolism. Several
clinical trials of statins have shown the beneficial effects on
serum LDL, HDL and triglyceride in nonuremic hyper-
lipidemic population [51]. )us, the effects observed in the
CKD rats are consistent with those founds in hyper-
lipidemic population.
5. Conclusion
In conclusion, CKD induced by an adenine-modified diet in
normal rats leads to the derangement of lipid metabolism.
)is is associated with the dysregulation of cholesterol and
triglyceride-rich lipoprotein metabolism. Long-term statin
administration to CKD animals corrects the observed
dyslipidaemia by improving cholesterol and triglyceride
metabolism. Furthermore, the present study provides evi-
dence of the renoprotective effects of atorvastatin in CKD
animals. We conclude that the present findings provide the
rational basis that the renoprotective strategies could be
effective in retarding the altered lipid metabolism in CKD
patients.
Data Availability
)e data used to support the findings of this study are in-
cluded within the article.
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Figure 3: Effects of atorvastatin on enzymatic activity of lipase in various tissues and serum of adenine-induced CKD rats. Lipase enzymatic
activity in (a) liver, (b) skeletal muscle, (c) heart, (d) adipose tissue, and (e) serum of rats treated for 24 days either with normal diet (control)
or adenine-supplemented diet (CKD) alone or with atorvastatin (CKD+ATV). Each bar represents the mean± SEM of 5–6 rats. Significant
difference from control: ##p< 0.01. Significant difference from CKD: ∗∗p< 0.01.
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